Immunotherapy (Pembrolizumab)

DRUG4 trials

Sponsors

CNAO National Center of Oncological Hadrontherapy, Linnaeus Therapeutics, Inc., The University of Texas Health Science Center, Houston, Peking Union Medical College Hospital

Conditions

Cutaneous MelanomaHead and Neck Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaMelanomaMelanoma (Skin Cancer)Melanoma Stage IIIB-IVNon Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Phase 2

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

RecruitingNCT05229614

CNAO National Center of Oncological HadrontherapyHead and Neck Squamous Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer +1

Start: 2022-07-26End: 2026-08-31Target: 27Updated: 2024-08-21

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

RecruitingNCT06624644

Linnaeus Therapeutics, Inc.Cutaneous Melanoma, Melanoma (Skin Cancer), Melanoma Stage IIIB-IV +1

Start: 2025-08-06End: 2031-02-01Target: 135Updated: 2026-04-22

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

RecruitingNCT06831136

The University of Texas Health Science Center, HoustonPancreatic Ductal Adenocarcinoma

Start: 2025-03-26End: 2030-01-20Target: 24Updated: 2025-09-10

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

RecruitingNCT06907602

Peking Union Medical College HospitalLocally Advanced Esophageal Squamous Cell Carcinoma

Start: 2024-01-12End: 2028-12-31Target: 120Updated: 2025-04-02